Principles of drug antitumor treatment against the background of severe cardiovascular pathology
https://doi.org/10.18705/2782-3806-2025-5-3-212-218
EDN: STNQFQ
Abstract
Modern oncology is faced with the problem of treating malignant neoplasms in patients with severe cardiovascular diseases, such as heart failure, coronary heart disease, hypertension, cardiomyopathy and rhythm disorders. Antitumor therapy (chemotherapy, targeted drugs, immunotherapy, radiation therapy) can exacerbate cardiovascular risks, which requires a special approach to the choice of treatment, minimizing risks and maintaining the effectiveness of antitumor therapy.
About the Authors
E. Yu. Zorina
Almazov National Medical Research Centre, Saint Petersburg, Russia
Russian Federation
Russian Federation
Zorina Ekaterina Yu., Candidate of Medical Sciences, oncologist of the highest qualification category
I. N. Danilov
Almazov National Medical Research Centre, Saint Petersburg, Russia
Russian Federation
Russian Federation
Danilov Ivan N., Associate Professor, Candidate of Medical Sciences, surgeon of the highest qualification category, oncologist, Head of the Department of Faculty Surgery with Сlinic
E. D. Kuzheleva
Almazov National Medical Research Centre, Saint Petersburg, Russia
Russian Federation
Russian Federation
Kuzheleva Elizabeth D., clinical resident oncologist of the Department of Faculty Surgery with the Clinic
L. A. Sinkevich
Almazov National Medical Research Centre, Saint Petersburg, Russia
Russian Federation
Russian Federation
Sinkevich Lilia А., laboratory assistant of the Department of Faculty Surgery with the Clinic
References
1. Bonsu J, Charles L, Guha A, et al. Representation of Patients With Cardiovascular Disease in Pivotal Cancer Clinical Trials. Circulation. 2019;139. DOI:10.1161/CIRCULATIONAHA.118.039180.
2. Sturgeon KM, Deng L, Bluethmann SM, et al. A population-based study of cardiovascular disease mortality risk in US cancer patients. European Heart Journal. Vol. 40, Issue 48, 21 December 2019, P. 3889–3897. https://doi.org/10.1093/eurheartj/ehz766
3. Gon Y, Zha L, Sasaki T, et al. Heart Disease Mortality in Cancer Survivors: A Population-Based Study in Japan. J Am Heart Assoc. 2023 Dec 5;12(23):e029967. DOI:10.1161/JAHA.123.029967. Epub 2023 Nov 28. PMID: 38014664; PMCID: PMC10727325.
4. Chazova IE, Ageev FT, Aksenova AV, et al. Eurasian clinical guidelines for cardiovascular complications of cancer treatments: diagnosis, prevention and treatment (2022). Eurasian heart journal. 2022;(1):6–79. In Russian [Чазова И.Е., Агеев Ф.Т., Аксенова А.В. и др. Евразийские клинические рекомендации по диагностике, профилактике и лечению сердечно-сосудистых осложнений при противоопухолевой терапии (2022). Евразийский кардиологический журнал. 2022;(1):6–79]. https:// doi.org/10.38109/2225-1685-2022-1-6-79.
5. Vasyuk YuA, Gendlin GE, Emelina EI, et al. Сonsensus statement of Russian experts on the pre vention, diagnosis and treatment of cardiotoxicity of anticancer therapy. Russian Journal of Cardiology. 2021;26(9):4703. In Russian [Васюк Ю.А., Гендлин Г.Е., Емелина Е.И. и др. Согласованное мнение российских экспертов по профилактике, диагностике и лечению сердечно-сосудистой токсичности противоопухолевой терапии. Российский кардиологический журнал. 2021;26(9):4703]. DOI:10.15829/1560-4071-2021-4703.
6. Belenkov YuN, Ilgisonis IS, Kirichenko YuYu, Murtuzaliev ShM. Cardio-oncology today: digest ofthefirst European clinical guidelines (2022). Kardiologiia=Cardiology. 2023;63(7):3–15. In Russian [Беленков Ю.Н., Ильгисонис И.С., Кириченко Ю.Ю., Муртузалиев Ш.М. Кардиоонкология сегодня: анализ первых европейских клинических рекомендаций 2022 года. Кардиология. 2023;63(7):3–15].
7. Shavarova E, Khachaturyan E, Pokatayev I, Kobalava Zh. Current diagnosis and treatment of arterial hypertension induced by antiangiogenic antitumour agents. Klinicheskaya farmakologiya i terapiya=Clin Pharmacol Ther 2023;32(2):32–36. In Russian [Шаварова Е.К., Хачатурян Э.А., Покатаев И.А., Кобалава Ж.Д. Современные алгоритмы диагностики и лечения артериальной гипертонии, ассоциированной с антиангиогенной противоопухолевой терапией. Клиническая фармакология и терапия. 2021;32(2):32–36]. DOI:10.32756/0869-5490-2023-2-32-36.
8. Vicenya MV, Ageev FT, Orlova RV, Poltavskaya MG, Potievskaya VI. Practical recommendations for the correction of cardiovascular toxicity of antitumor drug therapy. Practical recommendations RUSSCO, part 2. Malignant tumors, 2023 (vol. 13), #3s2, pp. 86–111. In Russian [Виценя М.В., Агеев Ф.Т., Орлова Р.В., Полтавская М.Г., Потиевская В.И. Практические рекомендации по коррекции кардиоваскулярной токсичности противоопухолевой лекарственной терапии. Практические рекомендации RUSSCO, часть 2. Злокачественные опухоли, 2023 (том 13), #3s2. С. 86–111]. DOI:10.18027/2224-5057-2023-13-3s2-2-86-111.
9. Somonova OV, Antukh EA, Vardanyan AV, et al. Practical recommendations for the prevention and treatment of thromboembolic complications in cancer patients. Malignant tumors: Practical recommendations RUSSCO #3s2. 2022 (vol. 120);12:159–170. In Russian [Сомонова О.В., Антух Э.А., Варданян А.В. и др. Практические рекомендации по профилактике и лечению тромбоэмболических осложнений у онкологических больных. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2. 2022 (том 120);12:159–170]. DOI: 10.18027/2224-5057-2022-12-3s2-159-170.
10. Ellis GK, Livingston RB, Gralow JR, et al. DoseDense Anthracycline-Based Chemotherapy for NodePositive Breast Cancer. Journal of Clinical Oncology. 2002;20(17):3637–3643. DOI:10.1200/jco.2002.12.113.
Review
For citations:
Zorina E.Yu., Danilov I.N., Kuzheleva E.D., Sinkevich L.A. Principles of drug antitumor treatment against the background of severe cardiovascular pathology. Russian Journal for Personalized Medicine. 2025;5(3):212-218. (In Russ.) https://doi.org/10.18705/2782-3806-2025-5-3-212-218. EDN: STNQFQ
Views:
19
Email this article 